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Circadian rhythms and mood:
Opportunities for multi-level analyses
in genomics and neuroscience
Circadian rhythm dysregulation in mood disorders provides clues to the brain’s
organizing principles, and a touchstone for genomics and neuroscience
Jun Z. Li
In the healthy state, both circadian rhythm and mood are
stable against perturbations, yet they are capable of adjusting
to altered internal cues or ongoing changes in external
conditions. The dual demands of stability and flexibility are
met by the collective properties of complex neural networks.
Disruption of this balance underlies both circadian rhythm
abnormality and mood disorders. However, we do not fully
understand the network properties that govern the crosstalk
between the circadian system and mood regulation. This
puzzle reflects a challenge at the center of neurobiology, and
its solution requires the successful integration of existing data
across all levels of neural organization, frommolecules, cells,
circuits, network dynamics, to integrated mental function.
This essay discusses several open questions confronting the
cross-level synthesis, and proposes that circadian regulation,
and its role in mood, stands as a uniquely tractable system to
study the causal mechanisms of neural adaptation.
Keywords:.circadian rhythm; dynamics; genetics; integrative
analysis; mood disorder; network; neurobiology
Introduction
A hallmark feature of mood disorders is disrupted circadian/
sleep patterns [1], a comorbidity well recognized at the
behavioral level. However, the causal relationship between
the two conditions (i.e. which comes first?) is not fully
understood. Our recent study of postmortem brain tissues
identified 24-hour cyclic patterns of gene expression in
healthy donors, and found that such patterns were disrupted
in patients of major depressive disorder (MDD) [2] (also
see [3]). This result uncovered the link between circadian
rhythm and mood at the level of gene regulation, and drew
attention to many bigger questions: How do sleep disruption
and other circadian abnormalities contribute to mood
disorders in general? What is the role of neural and
physiological rhythms in mental health? And how can
genomic datasets and systems biology help us answer these
questions?
Although exciting progress has been made in clarifying
the biochemical and cellular mechanisms of brain func-
tions, neural network properties remain difficult to study,
and will be the focus of this essay. I will briefly review
the current state of knowledge of circadian system and
mood regulation, highlighting network properties and
system dynamics as key mediators of neural plasticity,
which underlies the circadian rhythm-mood connection.
I will provide a quick tour of relevant gene expression
and genetic studies, summarizing their progress and
limitations. I will describe opportunities to achieve at
least modest successes in bridging the gene-level, cell-
level, and circuit-level research, and discuss open ques-
tions that represent major hurdles facing the synthesis of
psychiatric genetics and systems neuroscience. Through-
out the essay, I will make the case that circadian regulation
is an ideal system for the initial tackling of these
challenges.
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Plasticity, hierarchical networks, and
dynamics are essential features of
circadian regulation
Physiological and behavioral circadian rhythms are main-
tained by a biological timekeeping capability that has evolved
in most of life on earth. In mammals, these rhythms are
controlled by the master oscillator, which consists of a group
of rhythmic cells located in the suprachiasmatic nucleus (SCN)
of the hypothalamus [4]. SCN rhythms are entrained by photic
input from the eye. Local oscillators in other brain regions and
peripheral tissues receive input from the SCN and integrate
this signal with other internal cues, such as body temperature
and hormone levels. Compared to other brain functions such
as emotion and cognition, circadian rhythm regulation is a
particularly attractive model to study. Its input can be readily
controlled by adjusting the timing and quality of ambient light.
Its readout is measurable, for example, as daily oscillations of
hormone levels or transcriptomic patterns in a given tissue.
Because circadian regulation is universal across most life
forms it is relatively easy to find animal models that are
generalizable to humans. For example, key genes involved in
intrinsic cellular rhythms in humans (i.e. “clock genes”) have
homologs in fruit flies and rodents; both are well-developed
systems for genetic and functional dissection. The cellular and
circuit-level organization of mammalian circadian regulation
has been extensively reviewed [5]. Of primary interest to this
essay are the higher-level features of the circadian system –
functional plasticity, network properties, and dynamics – and
their relevance to other integrated mental functions.
Functional plasticity: A good clock is reliable and
adjustable
Circadian regulation is a quintessential example of functional
plasticity, as it demonstrates the balance between consistency
and flexibility. The baseline rhythms, particularly in the SCN,
are robust to genetic and environmental perturbations [6, 7].
However, these rhythms can adapt to major changes in the
operating environment, including seasonal changes of day
length, and, in the case of modern humans and experimental
animals, sudden changes in daily light schedule [5, 8]. Evolution
has enabled the circadian system to respond to gradual seasonal
changes. However, rapid phase resetting as demanded by air
travel or shift work is an evolutionarily recent, novel stressor;
and the mammalian circadian system is capable of responding
to such acute demands. Even so, while most people can make
the transition to a new schedule, frequent shifts can lead to
long-term health consequences, such as increased risk of
cardiovascular and immune dysfunction.
Network properties: No clock works alone in the
circadian system
In the SCN, rhythms are maintained as both single-cell and
ensemble properties. Each SCN neuron generates intrinsic
rhythmicity through interlocking feedback loops involving a
set of “core clock genes” and their protein products. Cell-
autonomous rhythms are synchronized at the level of cell
populations. The SCN exerts top-down control over other
brain regions and peripheral oscillators while receiving
feedback from them. Thus, the circadian control system is a
hierarchical network, involving “elementary clocks” in
individual cells, “ensemble clocks” in cell populations,
coupling between central and peripheral oscillators, and
interactions with external input [9] (Fig. 1). As an analogy,
different oscillators behave like sections in an orchestra –
within each section every member (the cell) is a self-sufficient
musician, and every musician plays in ensemble by listening
to the others and following a rhythmic input (the daily cycle of
environmental light). Each section has its distinct role, but
harmonizes with the other sections via a precise phase
relationship. There exists a standard temporal protocol, but it
is possible to vary it or to reset the phase relationship. Healthy
operation of the system relies on both central control and local
autonomy, and the right level of plasticity. Compared to
isolated cells, ensemble rhythms of the network are more
resistant to genetic or environmental perturbations [6, 7, 10],
serving as a reminder that circuit-level properties are central
to any effort to understand brain function.
Neural dynamics: The circadian system provides
an ideal model to study temporal organization
In the SCN, adaptation to seasonal changes of day length or
temperature is achieved not by changed oscillating properties
of individual neurons but by the altered phase relationship
among them [11, 12]. Circadian regulation thus provides an
ideal model to study the role of temporal organization. The
master-subordinate relationship between the SCN and other
oscillators is known; so is the core set of 10–20 genes and how
they interact with each other to maintain cell-autonomous
rhythms. The next several hundred genes in specific tissues
have begun to be recognized in genomic studies. There is a
wealth of existing data on the wiring diagram and connection
parameters for both intra- and intercellular interactions [13].
The dynamic behavior of circadian oscillators has been
extensively modeled (e.g. [14]), allowing quantitative under-
standing of coupling strength, phase distribution, and their
consequences [15]. In the example of recovery from jet lag, one
can ask somemodestly ambitious questions as a starting point
for understanding mechanisms of resynchronization and
stability: Since the dorsal and ventral regions of the SCN show
different response speeds to light schedule changes [16], how
do the two circuits regain phase cohesion? How does the
tissue ensemble transition from one stable state to another?
Can the mechanisms of phase resetting teach us something
about neural regulation in other systems?
Relevance to other systems: Everything happens
in its own time, for a reason, and together
Adaptation in other mental functions, including mood, is also
best understood in terms of network properties, including
intrinsic dynamics, responses to stress, and alternative (meta)
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stable states. This essay is partly inspired by the premise that
the manner in which the brain manages the synchrony and
asynchrony of neuronal populations is crucial to its normal
operation. Circadian rhythm regulation is not the only
example where temporal patterns in neural circuits – rather
than constitutional features such as static levels of neuro-
transmitters – encode the function of the system andmark the
divide between health and disease [17, 18]. In animal models,
short-term dynamic modulation of synaptic plasticity is
correlated with behavior in a working memory task [19].
Some cardinal symptoms of depression and schizophrenia are
linked to aberrant timing in information processing [20].
These results strongly suggest that inter-circuit coupling and
timing could be a universal mechanism for network-level
function, and that impaired temporal organization could
manifest as behavioral deficits [21]. Further, since maladapta-
tion may arise from an inability to regain proper synchrony,
this network-level phenotype can be a target for therapy; for
example, clinical data show that social rhythm stabilization
can improve recovery from bipolar depression [22, 23].
Circadian rhythm and mood regulation share a similar
temporal scale. The adjustment to jet lag takes many days to
harmonize across oscillators, despite the fact that ventral
SCN itself is entrained quickly [16]. The characteristic tempo
of this form of inter-circuit plasticity, spanning days to
weeks, is reminiscent of the mood cycling time in bipolar
disorders (BD) and the therapeutic delay observed for
classic antidepressants, which take 2–4 weeks to work fully
(in the case that they are effective for that individual). Could
circadian phase flexibility share a common mechanism
with mental resilience [24]? Do patients with depression
exhibit different patterns of synchronicity between oscillators
compared to healthy subjects, reflecting too much or too
little plasticity? Can we discover causal network features for
a brain disease as opposed to causal molecular or cellular
features?
Circadian system and mood disorders
are linked at the behavioral and
molecular levels
Mood disorders such as severe depression are one of the
central problems in neurobiology and psychiatry. Currently,
studies of mood disorder pathophysiology have implicated a
staggering array of biological processes (for a review, see [25]).
Of particular interest to this discussion, MDD and BD engage
neuroplasticity at multiple levels. At the behavioral level, the
depressed state can be induced by external stress factors as
an adaptive response (i.e. beneficial to the subject under the
circumstance). After the initial response, many people recover
to a normal state, demonstrating resilience. Yet in others,
depression becomes a stable state, even resistant to treatment
Figure 1. Hierarchical organization of the circadian system. A:
Rhythmicity within a cell is generated by feedback regulations
among core clock genes. B: Synchronization among cells produces
robust, ensemble rhythms in a population. C: The SCN exerts top-
down control over other oscillators, and receives external input,
indicated by the sun, as well as feedback from peripheral clocks.
Phase relationships among oscillators are stable, yet they can also
adapt to changed light schedules. D: Dynamic regulation and
dysregulation of circadian clocks affect behavioral outcomes.
....Prospects & Overviews J. Z. Li
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(Fig. 2). The exact mechanism by which the brain enters and
locks into a depressed state, even when it is no longer
beneficial, remains elusive. As such, proper mood regulation
requires a balance between stability and plasticity, resembling
the dual demand observed in circadian regulation.
Circadian abnormality can be both a causal factor and
consequence of psychiatric disorders. For some people,
troubled sleep adds to their stress level and provokes the
onset or worsening of depression; while for others sleep
disruption may be secondary to depression and/or receiving
medical treatment. Clock dysfunction is closely intertwined
with mood disorders in animal models. Mice carrying a
dominant-negative mutation of the Clock gene show sleep
disturbances, but also manic-like behavior, which can be
reversed by lithium, a common mood-stabilizing drug [26].
Such observations confirm a strong genetic link between
circadian clock and mood regulation, although they do not
resolve the causal relationship between the two in humans.
Past studies have uncovered numerous mechanisms to
explain the connection between circadian rhythm disruption
andmood disorders (reviewed in [27]). These two functions are
linked bymonoamine signaling [26, 28] and immune function,
as mediated by the proinflammatory cytokines [29] (but also
see [30]), the hypothalamic-pituitary-adrenal axis and
glucocorticoids, metabolic factors such as peptides regulating
eating behavior, general mitochondrial function, and neuro-
genesis [31, 32]. Much of this impressive literature is populated
by molecular and cellular findings. However, additional
studies are needed to sort out the relative importance of the
diverse lineup of molecular/cellular factors. In which brain
circuits do they act? Under which environmental conditions?
At which stage of brain development? How do they influence
network dynamics and behavioral output?
What can be learned from gene
expression studies?
In recent years, the challenge of knowledge integration in
studies of complex traits was amplified by the influx of larger-
scale data, particularly from gene expression and genetic
analyses. Gene expression profiling belongs to the new
discipline of Functional Genomics, which applies high-
throughput methods to study the function, regulation, and
interaction of all measurable molecular components of a cell
or tissue system. While these components include DNA, RNA,
proteins, and metabolites, here I will focus on transcriptomic
changes that accompany circadian cycling.
In non-human animals, circadian cycles of gene expression
have been demonstrated in the blood, brain, liver, kidney,
skeletal muscle, and heart [33–36]. Parallel studies in humans
have been limited to easily accessible tissues such as the oral
mucosa [37], skin biopsies [38], hair follicle cells [39], and
cultured cell lines [40, 41]. In a recent study [2], we extended
whole-transcriptome analyses to the human brain, using
postmortem tissues obtained from six cortical and limbic
regions (not including the SCN). Our results show that circadian
patterns do exist in the transcriptome of healthy donors, and
are in-phase across the six regions analyzed. The patterns
involve several hundred transcripts, led by the best-known
clock genes such as BMAL1. The data suggest that gene
expression rhythmsmust be stable, as the cyclicitywas detected
over 55 brain donors, each representing a single time point in
the overall 24-hour cyclic patterns. The donors experienced
different acute medical conditions at death, thus our findings
re-affirm the robust and slow-changing nature of the circadian
rhythm: Even though some genes respond rapidly to external
factors, even on a time-scale of less than one hour [42, 43], the
daily cycling of known clock genes is impervious to sudden
changes in environmental cues outside of the SCN.
Our study still left many questions unanswered. First, the
medical records of the study participants did not describe
the quality, duration, or phase of sleep at their final days of
life, precluding an answer to the what-comes-first question.
Second, as a general limitation in bulk tissue analysis, studies
of large brain regions can only report the average profile of
all cells in the population. Future studies of the brain
transcriptome need to take spatial heterogeneity into account,
and must address other prominent sources of biological noise
such as medication history and agonal conditions [44].
Despite these limitations, gene expression analysis
remains a powerful tool for reading out the cellular and
Figure 2. Health and disease can be conceived as two inter-
convertible, metastable states, depicted as troughs in an energy
landscape. A: Stressful situations, coupled with intrinsic vulnerability
including genetic predisposition, may shift the healthy state into
an alternative and relatively stable state that has adaptive value.
B: Sometimes the adaptive state may be “locked” in, and becomes
a maladaptive disease state. It is difficult to restore health when the
disease is locally stable, with a high barrier blocking the return path
to health. The situation is akin to the classic concept of canalization.
Understanding the network properties that govern system stability
will guide the development of better therapies that can tilt the
landscape in favor of health, or lower the barrier by finding more
effective drug targets.
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biochemical disturbances in specific brain regions – assuming
that such signatures are observable at the spatial resolution
attempted, and remain at the time of tissue collection. This
approach provides a useful complement to the classic genetic
methods because causal genetic factors only provide the
innate proclivity of a trait, a yet-to-be-realized susceptibility.
In contrast, gene expression profiles of the mature tissue
capture the present state, and may reveal proximal causal
mechanisms (Fig. 3). If the varied assortment of contributing
factors, both genetic and environmental, converges on a
smaller number of functional states, analysis of the tran-
scriptomic correlates of phenotypic outcome can be more
powerful and more informative than simply trying to detect
the genetic correlates.
Genetic studies of circadian rhythms
and psychiatric disorders brought
limited returns
In humans, while many DNA variants can perturb the amount
and biochemical function of the gene products, only a subset
of them can penetrate all the intermediate levels (e.g. cells
and circuits) to affect emotion and behavior. The goal of
genetic studies is to understand the “architecture” of genetic
influence and identify the causal variants among the many
naturally occurring but phenotypically neutral variants.
Mendelian and common forms of sleep disorders
cover a spectrum of genetic effects
Several Mendelian forms of sleep disorders have been
described [45]. A pedigree of familial advanced sleep phase
disorder (FASPD) carries a S662G variant in hPer2, a human
homolog of the period gene in Drosophila, a core clock
gene [46]. When tested in transgenic mice, the S662G change
recapitulated the human phenotype [47]. Similar discoveries
were subsequently made for other clock genes in additional
pedigrees of sleep disorders [48, 49]. Meanwhile, mouse
models of Clock, Npas2, Bmal1, Cry1, and Cry2 show altered
sleeping traits (reviewed in [45]). Collectively, these studies
provided convincing support for the importance of core
clock genes in regulating sleep behavior. Notably, the loss
of a single clock gene in animal models is often insufficient
to disrupt normal rhythms unless environmental time
cues are also disrupted. In the normal environment,
multiple genetic defects are often required to elicit altered
behavior [10], demonstrating robustness against genetic
perturbations.
In humans, the prevalence of Mendelian sleep disorders is
not accurately known, but they are likely rare. The population
burden of common sleep disorders is yet to be defined. Twin
studies have shown that sleeping traits have a moderate
genetic component in the general population, with narrow-
sense heritability in the 30–40% range [50–53]. Candidate
gene-based association studies of common circadian rhythm
disorders have focused primarily on known clock genes and
have been reviewed previously [45].
Unlike candidate gene studies, genome-wide association
studies (GWAS) enable an unbiased search beyond known
candidates. To date, three GWAS have been conducted
for sleeping traits, and have identified association signals
near the NPSR1 and PDE4D genes [54], in CACNA1C,
encoding an L-type calcium channel [55], and ABCC9,
encoding an ATP-sensitive potassium channel [56].
Attempts to replicate the CACNA1C signal have produced
mixed results [55, 57]. Notably, none of the core clock genes
reached genome-wide significance in these GWAS, suggest-
ing that, with the sample size currently available, the
association between common variants in known clock
genes and common circadian rhythm traits have not yielded
replicable results.
Figure 3. Genetic association studies look for
remote causal links between genotype and
phenotype, while gene expression analyses
explore proximal correlations between the tran-
scriptome and the outcome. During the life
history of an individual, shown along the arrow,
inherited genetic variants provide a background
predisposition as a person-specific “trait”, which
acts in most cells, tissues, and life stages, but
may or may not manifest as a disease “state”.
The disease state varies by cell type, tissue
type, and the time window, and critically,
reflects the cumulative influence of the person’s
unique environments and life experience. A
positive genetic association is detectable only if
the DNA variant has a sufficiently strong impact,
such that the causal link can persist through all
the intermediate levels of organization. Gene
expression analysis, in contrast, reports the
present state of gene regulation in a specific
tissue, and reflects the gene-environment inter-
actions in the recent past.
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GWAS for psychiatric disorders: Large
community efforts, variable yields
An extensive literature exists regarding linkage analyses and
candidate gene association studies of psychiatric traits. Taken
together, candidate gene-based association for complex traits
has a lackluster history, marked by poor reproducibility [58,
59]. Here, I will focus on GWAS, in which the statistical
threshold is higher than for candidate genes, but the signals
that did achieve genome-wide significance have proven to be
more reproducible. Dozens of GWAS have been conducted for
five mental disorders: MDD, BD, schizophrenia, autism, and
attention deficit hyperactivity disorder; andmanymore GWAS
are added every year. A meta-analysis of MDD (11,215 patients
and 9,761 controls) did not identify risk loci with genome-wide
significance [60]. A similar analysis of BD (11,974 patients and
51,792 controls) identified CACNA1C, a calcium channel, and
ODZ4, encoding a cell surface protein [61]. A meta-analysis of
schizophrenia (n> 50,000 patients and controls) implicated
22 loci [62, 63]. Pathway analysis showed that calcium
channels are enriched in BD association intervals. Of note, the
CACNA1 gene was among the top findings in the GWAS for
sleeping traits described above [55], suggesting a potential
common genetic link between sleep and mood disorders.
The polygenic nature of psychiatric disorders
brings new challenges
A meta-analysis of GWAS for schizophrenia suggested a
polygenic model, involving common alleles across thousands
of loci, each contributing very small effects [64]. Since then,
a polygenic genetic architecture has been similarly reported for
other complex traits such as multiple sclerosis and body mass
index [65, 66]. Combined analyses of the five psychiatric
diseases mentioned above, including 33,332 cases and 27,888
controls, demonstrated strong cross-disorder genetic over-
lap [67, 68]. Four regions, including CACNA1C, were associated
with all five disorders. Among MDD, BD, and schizophrenia,
risk scores calculated from polygenic signals in one disorder
can explain a statistically significant (albeit small) portion of
the variance of a second disorder, particularly between BD and
schizophrenia, suggesting shared genetic etiology spreading
numerous loci. The latest analysis of schizophrenia implicated
6,300–13,200 independent SNPs [63].
The findings described above have provided deeper
insight into the genetic basis of psychiatric disorders, but
they have also brought us head-on into the next puzzle: How
to make use of these findings? The polygenic scores, while
compelling in a statistical sense, are remarkably diffuse in a
biological sense. The sheer number of risk factors has no
parallel in the history of epidemiology. For a study cohort, the
inherited risks are apparently spread over thousands of loci
and subtly implicate numerous genes and pathways. Howev-
er, for an individual patient, does he/she come to develop the
disease by equally dispersed biological routes? Or, could
the polygenic signal be merely illusory, formed by pooling
large numbers of patients with heterogeneous causes, each of
whom develop a disease due to far fewer variants, but of
higher phenotypic impact [69]? If the latter is true, what is the
best way to identify the heterogeneous, patient-specific
genetic factors? Questions such as these are the subject of
ongoing debate and are discussed further in Box 1.
Rare, high-impact variants take center stage
To date, genetic studies have identified ABCC9 and possibly
CACNA1C for common sleeping traits, CACNA1C and ODZ4 for
BD, no significant signals for MDD, 22 associated regions for
schizophrenia, and broad, polygenic signals shared across
multiple disorders. These GWAS, however, have not identified
any core clock genes with genome-wide significance. Taken
together, we currently have very few specific DNA variants
with large effects to motivate experimental follow-up,
especially at the interface of circadian rhythm and mood
regulation. Polygenic signals andmost pathway findings carry
limited specificity. For example, when a psychiatric disease is
said to involve hundreds of genes that, as a whole, are
Box 1
Limitations of the polygenic
understanding of psychiatric
disorders
Polygenicity may turn out to be the fundamental truth
for most common human diseases, and its discoverymay
be the overriding achievement of the GWAS approach
[70, 71]. However, the lack of specific molecular clues
remains a dark cloud over complex trait genetics,
threatening its relevance as a source of useful insights.
There have been two anticipated utilities of GWAS
findings. The first is prediction of disease outcome – the
“risk engine”, similar to an actuarial table, and the second
is mechanistic understanding – the “wiring diagram” of
biology [72]. Currently, the predictive power of the
polygenic signals is quite limited: It mostly does not
outperform traditional risk factors such as family history
and is unlikely to improve dramatically in the near future.
Much attention has thus been turned, understandably, to
the task of distilling genetic findings into pathway signals
that may guide further research [70]. There has been
much recent progress in tool development and pathway
annotation [73, 74], leading to a steady streamof pathway
findings [75, 76]. Pathway results, however, often lack
sensitivity and specificity, because they come from (i) in
silico literature mining, requiring that the connection has
already been publishedbefore and is formally searchable,
or (ii) enrichment analysis of generic gene annotation,
which is currently incomplete, rapidly changing, and
rarely addresses specifically the particular brain circuits,
symptoms, or developmental stages. In this regard, new
efforts to develop functional annotations for specific life
stages and specific cell types represent a promising
direction, and have begun to yield more disease-specific
pathway findings [77].
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enriched for neurodevelopment or synaptic transmission, the
notion lies closer to the question than to the answer, as it is
hardly a novel insight that brain disorders will likely involve
neurodevelopment and neural transmission. In the absence of
a credible molecular target, these results also do not lead to
clearly falsifiable predictions.
In the near future, given the paucity of unequivocal leads,
it is profitable to focus on de novo, Mendelian or nearly
Mendelian cases, using rare DNA variants of large impact as
the source of informative genetic perturbation. The increased
availability of DNA variation data in the general population,
produced by large-scale DNA sequencing in studies of other
human diseases, opens up opportunities of finding genetic
signals of testable consequences. For example, it would be
quite interesting to ask if carriers of loss-of-function mutations
in core clock genes present altered sleep habits or some forms
of previously unrecognized sleep disorders. If the answer is no,
the next interesting question is how molecular defects in key
clock genes could be compensated at the physiological level. If
the answer is yes, the identified individuals, with reverse-
ascertained circadian abnormalities, would provide exciting
new models to probe the molecular interactions underlying
circadian regulation. Logistically, this genotype-looking-for-
phenotype approach will be greatly aided by a national or
international registry of genetic variants of unknown func-
tional significance. When call-back phenotyping becomes
feasible, it could extend from sleep behavior to mental
function parameters, providing the much needed epidemio-
logical data to address the chicken-versus-egg question.
An integrative framework as the new
frontier
In the following, I will assume that at a certain point in the
future we have indeed obtained a series of DNA variants that
strongly impact circadian rhythms or mood regulation, and
consider the question: How can these results be useful to
neurobiologists to help them explain disease mechanisms?
Sincewe donot fully understand the components and governing
principles of neural systems, a central task is to apply the right
experimental tools to support a chosen level of analysis. The
standard toolkit of neurobiology offers an impressive arsenal of
techniques for every level. For example, electrical recording can
be performed in dissociated cells, in brain slices, or in vivo.
Available cell models include cultured olfactory neurons [78],
skin fibroblasts [79], or induced pluripotent stem cells [80]. At a
higher level, brain imaging can capturemorphometric or activity
measures in many brain regions. The challenge at the new
frontier is in integrating these tools to further a cross-level
understanding: From causal genes to causal networks, with
causal dynamic patterns of neural activity that are predictive of
circadian rhythms and/or affective states.
How might this integration take place?
To illustrate how all the tools and data can be marshaled
under an integrative “framework”, I will use a hypothetical
scenario. Let us suppose that, first, genetic or gene expression
data have implicated a calcium channel gene in mood
disorders. And second, screening of Mendelian families or
de novo cases has identified rare mutations with a strong
predicted impact on channel function. Using this genetic lead,
we can screen the general population to identify additional
subjects carrying high-impact mutations in this gene, and
in the meantime, develop targeted animal models such as
gene-disrupting transgenics or optogenetic models. Using
these human subjects or animal models, we can pursue
the pathophysiological relevance of the mutations at
multiple levels simultaneously (see Box 2). While none of
the experiments in Box 2 addresses the complete mechanism,
the multi-level data from the same sample series have the
best chance to “fill in” the succession of gaps from genes
to behavior. And the experiments, when driven by concrete
genetic hypotheses, have the best chance to unravel the
causal relationships in the system.
Box 2
Simultaneous multi-level
characterization of suspected
high-impact genetic variants
(1) In a cell system, we may determine whether the risk
variants alter the expression level of the channel
protein or its functional properties, such as conduc-
tion capacity or ion selectivity.
(2) At the synaptic level, we may use brain slices to
show aberrant localization of the variant protein,
or demonstrate altered plasticity, e.g. stronger or
weaker long-term potentiation.
(3) For a network-centric approach, we may find that
carriers of high-risk variants exhibit altered brain
activity in a specific cortical network or an abnormal
connection between two such networks.
(4) For dynamic properties, a neural firing unit may show
an atypical frequency or amplitude of oscillation, or
become out of phase with another unit.
(5) Developmentally, there may be delayed pruning of
neural processes in a specific cortical layer, or
diminished neurogenesis in the adult hippocampus.
(6) At the behavior level, wemay test sleeping traits such
as the length, phase, and quality of sleep [81].
(7) For global gene activity profiles, we may apply
transcriptomic or metabolomic analysis and identify
signatures previously seen in patient samples.
(8) To zoom in to study a particular time period or
specific cell types in vivo, we may apply optogenetic
methods to control the intensity and temporal
pattern of focal activation [82].
(9) To study genetic interaction, we may create
additional transgenic rodents either in a defined
background, or introduce the candidate variants into
a complex background such as the high-diversity
outbred lines.
....Prospects & Overviews J. Z. Li
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Because circadian regulation represents a uniquely workable
system, it is suitable as the testing ground of this integrative
research program. For example, coupling between the SCN
and other oscillators should be contrasted between
the mutation carriers and normal controls, especially in the
context of dynamic network properties. Specifically, since
the master oscillator resides in a well-defined anatomical
unit, the SCN, a valuable focal point of research is to
interrogate the strength and phase of functional coupling
between the SCN and other brain oscillators [83, 84], such as
the locus coeruleus, which regulates the transition from
attention to behavioral flexibility [85], or amygdala, which
regulates fear, anxiety, and depression symptoms. These
experiments will directly address if, and how, a single genetic
mutation can affect small-circuit plasticity,
temporal coordination among networks,
and behavioral outcome [16].
In practice, the best efforts of cross-level
integration may break down. For example,
despite clear evidence for the involvement
of the monoamine neurotransmitters at
the cellular and pharmacological level,
PET studies could not correlate depression
severity to the distribution and occupancy
of monoamine receptors/transporters [86].
In animal models, an engineered genetic
defect often fails to impinge on cellular or
circuit phenotypes because of (presumably)
compensatory effects of other genes. Some-
times, it takes two genetic defects to elicit a
disease-like condition, but only in a certain
genetic background or under certain envi-
ronmental stress. In this regard, circadian regulation and its
role in mood disorders present the opportunity to clarify the
power and limitations of multi-scale integration.
Three hurdles: Developmental timing, nonlinear
system, and ontological mismatch
The difficulty of translating genetic findings to physiological
explanations is rooted in the unexplained coupling between
different levels of biological organization, and the critical
dimension of time, involving both developmental timing and
network dynamics (Fig. 4). Neural outputs such as emotion,
cognition, and behavior are not directly coded, or understood,
Figure 4. Multi-level integration in complex trait studies, with the interplay between circadian
system and mood regulation as an example. From left to right are successive levels of
biological organization, starting from the molecular level, passing the cellular and network
levels, before reaching the phenotypic outcomes. From genes to cells, cells to circuits, and
onto outcomes, the interactions are many-to-many, and involve mechanisms that are often
poorly understood. These knowledge gaps are shown as black-bordered boxes between
adjacent levels. Some causal relationships only act “locally”, e.g. a DNA variant may affect a
specific cellular phenotype, while that phenotype may fail to affect any network in the next
level. Developmental timing adds a new dimension, shown as multiple sheets stacked on
each other, each with its own multi-level interactions. Some interactions are nonlinear and
iterative, e.g. circadian rhythm abnormality and mood disorders can each be the cause or
the consequence of the other. Molecular interaction within cells, shown in a network diagram
on the lower left, have been the focus of gene expression pathway analysis, functional
module annotation, and genome informatics, but they are distinct from, and do not address,
the intercellular networks that encode circuit-level features. The latter has its own
experimental data and emergent properties, requiring its own algorithms and informatics.
The dynamic property of neural networks is an essential level of inquiry, and the key to
understanding its plasticity and its effects on behavior, emotion, and disease outcome.
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by properties of single cells or bulk tissue averages. Rather,
the brain works as spatially distributed hierarchical neural
networks, molded by an individual’s genetics, early develop-
ment, and life experience. If much of the initial impairment
takes place during a critical period of brain development, as is
plausible for BD and schizophrenia, adult-onset symptoms
may merely occur as aftershocks of an unobserved earlier
distress. The ideal strategy for probing the temporal sequence
of brain disorders is to collect the longitudinal series that
covers the relevant episodes, but this is always a daunting task
in human studies. In short, we still lack suitable data to leap
this hurdle.
An even greater challenge lies in understanding the
iterative, nonlinear interactions between genes and environ-
ment. A long-standing riddle in psychiatric illnesses is the
contrast between their diverse plausible causes and the
accelerated appearance of distinctive symptoms. This contrast
echoes the deeper contradiction that knowledge in epidemi-
ology is statistical, yet the practice of medicine is personal.
From the statistical point of view, genetic predisposition in
most cases appears to be thinly distributed over thousands of
loci [63]. Similarly, neural deficiencies in any population of
patients implicate a widemix of neurotransmitter systems and
brain regions. However, at the individual level, the clinical
presentations are clustered, distinctly recognizable, and
often strongly familial, suggesting a restricted number of
archetypal disturbances, possibly involving a small number
of genetic origins, neurotransmitters, and brain circuits.
This implies that in the natural history of a given patient,
the interactions between his/her unique genes and unique
environment must be dynamic, convergent, self-organizing,
and self-reinforcing, bearing resemblance to the classic idea of
canalization [87, 88]. New analytical algorithms are needed
to capture such a clearly nonlinear system, as the current
case-control studies are primarily designed to screen for
simple, stable effects shared across a large cohort.
Lastly, we face an ontological mismatch between the
working concepts of different disciplines. As an analogy,
something as simple as water has many levels of understand-
ing: The structure of H2O does not automatically explain its
taste, wetness, or how it makes the floor slippery. Likewise,
the fundamental units of genetic analysis – genes, their
expression patterns in time and space, and pathways – remain
to be aligned with the fundamental units of neuroscience:
cells, chemical synapses, local circuits, their plasticity, and
the dynamics of large networks. They both remain to be
connected to system-level neural correlates, such as temporal
synchronization of transient neuronal assemblies. Network
properties are, at least in principle, objectively measurable,
yet they remain to be bridged to behavior or emotion, as
subjectively acted or experienced.
Concluding remarks
The dizzying progress in the fields of genomics and
neuroscience make it easy to forget that many scientific
hurdles remain to be overcome. A recent reminder of these
hurdles is the discussion of how psychiatric diagnosis has yet
to be connected to mechanistic footing [89, 90]. In this essay,
I draw attention to technical limits and pressing conceptual
challenges in both fields: In genetic studies, statistical
evidence of association remains to be elevated to functional
explanations that are experimentally testable. In neurosci-
ence, the challenge lies in uniting the data and tools across
multiple levels of analysis. In this regard, circadian regulation
allows concurrent studies on multiple scales, strengthening
the link between DNA variation, cellular activities, neural
circuitry, its dynamics and plasticity, and mood and
cognition. The analysis of the circadian-mood system provides
an exceptional opportunity for developing mechanistic
insights into nonlinear biological systems, and will be a
testing ground for the best tools in both genomics and
neuroscience. It is also suited to study the situation in which
the mechanistic link breaks down. Such a case disrupts the
existing best model and will help spell out how a high-level
feature becomes irreducible, or how a massive amount of
low-level data becomes intractable. Thus, the advances or
stagnation of this research will yield valuable lessons for
tackling other brain functions and other multi-level problems
in biology.
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